InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.420 -0.04 (-8.70%)+
Announcement
Release
21 Aug 2026 8:56AM
Price at Release
$0.460
Full Release
download
Summary
Island Pharmaceuticals Limited has initiated a second manufacturing campaign to significantly expand its supply of GMP-grade Galidesivir in response to the rapidly spreading Bundibugyo Ebola outbreak in Central Africa. The outbreak has resulted in over 5,200 confirmed cases and nearly 2,500 deaths, underscoring the urgency of having readily deployable antiviral treatments. Galidesivir, a broad-spectrum antiviral, will be available in approximately 700-800 treatment courses by the end of CY26. The strategic move supports the company's engagement with government and biodefense agencies and aligns with the WHO's MEURI framework for emergency use during outbreaks.
Key Points
  • Island Pharmaceuticals Limited has commissioned a second manufacturing campaign of GMP-grade Galidesivir to expand its supply.
  • This decision is strategic to address the ongoing Bundibugyo Ebola outbreak in Central Africa.
  • The outbreak has reported 5,208 confirmed cases and 2,476 deaths as of 18 August 2026.
  • Galidesivir is positioned as a broad-spectrum antiviral and biodefense countermeasure.
  • The company plans to deploy Galidesivir under the WHO's MEURI framework in Uganda during CY26.
  • Approximately 700-800 treatment courses of Galidesivir will be available by Q4 CY26.
  • Galidesivir has demonstrated strong efficacy in non-human primate models for multiple filoviruses.
  • The company's strategy includes engaging with governments and biodefense agencies for procurement and stockpiling.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.